SAN DIEGO, Dec. 13, 2017 /PRNewswire/ -- Genalyte, Inc. announced today that CEO and founder Cary Gunn will publicly debut the company's state of the art diagnostic testing approach in San Francisco, CA during the 36th annual J.P. Morgan Healthcare Conference, January 8-11, 2018.
Genalyte will create a patient testing lab station to coincide with leading health care conferences occurring in San Francisco throughout the week. Conference attendees, investors and members of the media will have the opportunity to personally experience the company's comprehensive blood testing service and rapid results delivery through free, voluntary participation.
Genalyte employs a cloud-based laboratory model to test and deliver high-quality, diagnostic results in the doctor's office. Results are available in approximately 15 minutes, allowing physicians to make informed diagnosis and treatment decisions while the patient is still present. Additional details on test location and times will be provided prior to the conference.
Genalyte's state of the art technology moves data—not blood—to transform the standard of care into a service that dramatically improves patient safety and outcomes. By digitizing blood samples, and moving data to a cloud lab facility, Genalyte delivers rapid, accurate results that drive better outcomes, lowers the overall cost of care and improves the patient experience.
Genalyte's mission is to empower doctors and patients to make better decisions that improve outcomes, lower overall costs, and make the diagnostics experience more effective. We employ a cloud-based laboratory service to bring diagnostic testing into the physician's office. Results are returned in approximately 15 minutes, eliminating the need for separate trips to the lab and waiting for results. For more information, please visit: www.genalyte.com.
SOURCE Genalyte, Inc.